Newsletter

October 2019 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: October Scorecard Number of Signals 20 Percent Correct – Prev Close to 5-day Peak 95% Avg Increase – Next open to 5-day Peak 9% Other stats: Number of signals over $10/share 10 Number […]

0Comments

Akorn Gets FDA Approval for Betamethasone Dipropionate Lotion USP (Augmented), 0.05%

Akorn, Inc. (AKRX) announced on October 14 that the company received FDA approval for betamethasone dipropionate lotion USP (augmented), 0.05%.  Akorn had filed an Abbreviated New Drug Application (ANDA) with the FDA. Betamethasone dipropionate lotion (augmented) is a corticosteroid indicated for the relief of dermatoses in patients 13 years of age and older. U.S. sales […]

0Comments

September 2019 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: September Scorecard Number of Signals 7 Percent Correct – Prev Close to 5-day Peak 71% Avg Increase – Next open to 5-day Peak 5% Other stats: Number of signals over $10/share 3 Number […]

0Comments

August 2019 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: August Scorecard Number of Signals 8 Percent Correct – Prev Close to 5-day Peak 88% Avg Increase – Next open to 5-day Peak 6% Other stats: Number of signals over $10/share 6 Number […]

0Comments

AbbVie Receives FDA Approval for RINVOQ

On August 16, AbbVie (ABBV) announced that it received FDA approval of RINVOQ (upadacitinib), a 15 mg, once-daily oral Janus kinase (JAK) inhibitor. The drug is expected to be available in the U.S. by the end of August 2019. RINVOQ treats adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate […]

0Comments

July 2019 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: July Scorecard Number of Signals 5 Percent Correct – Prev Close to 5-day Peak 80% Avg Increase – Next open to 5-day Peak 17% Other stats: Number of signals over $10/share 3 Number […]

0Comments

FDA Transfers BIVIGAM and Nabi-HB Licenses to ADMA Biologics

On July 8, ADMA Biologics, Inc. (ADMA) reported that they now hold the licenses for BIVIGAM and Nabi-HB that previously belonged to Biotest Pharamceuticals. This was the final regulatory item outstanding from ADMA’s acquisition of the Biotest Therapy Business Unit in June 2017. The FDA had to revoke the license from Biotest Pharmaceuticals and perform […]

0Comments

June 2019 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: June Scorecard Number of Signals 15 Percent Correct – Prev Close to 5-day Peak 21% Avg Increase – Next open to 5-day Peak 19% Other stats: Number of signals over $10/share 13 Number […]

0Comments

Krystal Biotech Reports Positive News from Phase 2 Clinical Trial of KB103

On June 24, Krystal Biotech (KRYS) reported positive news from its Phase 2 clinical trial of KB103. The treatment was effective and well tolerated by patients suffering from recessive dystrophic epidermolysis bullosa (RDEB). In addition, the FDA awarded Regenerative Medicine Advanced Therapy (RMAT) status to Krystal Biotech for KB103. Krystal Biotech is a gene therapy […]

0Comments

Ziopharm Receives FDA Clearance for IND with the National Cancer Institute

Ziopharm Oncology (ZIOP) announced on June 11 that the FDA approved an investigational new drug (IND) application as part of a research and development project the company has with the National Cancer Institute. They will now begin clinical trials in solid tumors to evaluate T-cell receptor (TCR) T-cell therapy that uses Ziopharm’s Sleeping Beauty platform. […]

0Comments

Latest of Knowledge Center